Searched for
INVAGEN PHARMACEUTICALS
Stocks in news: Tata Motors, GMR Airports, Jubilant Industries, Cipla, Lloyd MetalsJaykay Enterprises has completed the execution of MoU with Philips Machine Tools India to synergistically expand each other's businesses on...- Cipla unit recalls one lot of medication in US due to seal integrity issueDrug major Cipla's subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues. InvaGen Pharmaceutical...
- Stocks in news: TCS, Delta Corp, Infosys, HCL Tech, Zaggle Prepaid, CiplaIT major TCS reported 9% growth in its net profit to Rs 11,342 crore. The Board has also approved a buyback proposal worth Rs 17,000 crore ...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- Cipla unit gets notice from US firm for termination of acquisition deal"Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice...
- India Inc's Jan-Nov M&A deal tally at $82 billion: ReportIn November 2017, there were 39 deals worth USD 3.2 billion.
- Cipla's subsidiary to acquire US-based Avenue Therapeutics for $ 215 millionAt the second stage, InvaGen or its affiliates will acquire the remaining shares of Avenue's common stock, for up to USD 180 million in the...
- Stocks in focus on April 16, 2018Here is a list of top stocks that are likely to be in focus in today's trading session.
- Cipla gets USFDA nod for generic version of Renvela tabletsThe approved product is a generic equivalent to the reference listed drug (RLD), Renvela tablets, 800 mg of Genzyme Corporation, said Cipla.
- Cipla gets USFDA nod for generic anti-depressant drugThe company's tablets are generic versions of Valeant's Wellbutrin XL tablets in the same strengths, Cipla said.
- Cipla seals Invagen and Exelan deals in USThe deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...
- Over 200 drugs under development, top 50 with $30 billion potential: CiplaElaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...
- PuraCap suit may impact Cipla's $550-million dealIn an email response seeking comment, PuraCap said its complaint was publicly available at the US District Court for the Southern District ...
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- Cipla's ratings unlikely to be impacted by US acquisitions: India RatingsIndia Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- Cipla surges on US acquisitions worth $550 millionCipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.
- US FDA approves Glenmark's Nabumetone & Hydroxyzine HydrochlorideGlenmark Pharmaceuticals Inc, US a subsidiary of Glenmark Pharmaceuticals has initiated the marketing and distribution of Nabumetone tablet...
Load More
